Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | CCR8 | P51685 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL608528 | 0.83 | ALDH1A1 (0.76) | ALDH1A1CCR8TSHRKMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL7438287 | 0.82 | ALDH1A1 (0.74) | ALDH1A1CCR8KMT2AKDM4EMAPT | |
| SCHEMBL6745643 | 0.80 | HDAC8 (0.64) | ALDH1A1CCR8ABL1RIN1KDM4E | |
| SCHEMBL6745644 | 0.80 | HDAC8 (0.64) | ALDH1A1CCR8ABL1RIN1KDM4E | |
| SCHEMBL7985454 | 0.79 | ABL1 (0.63) | ALDH1A1CCR8ABL1RIN1MEN1 | |
| SCHEMBL3317577 | 0.79 | L3MBTL1 (0.71) | ALDH1A1CCR8KMT2AKDM4EMAPT | |
| SCHEMBL1545229 | 0.78 | L3MBTL1 (0.74) | ALDH1A1CCR8KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL8263564 | 0.78 | L3MBTL1 (0.74) | ALDH1A1CCR8KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL14022760 | 0.78 | L3MBTL1 (0.74) | ALDH1A1CCR8KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL592839 | 0.78 | MEN1 (0.66) | ABL1RIN1MEN1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625905-B2 | Octahydro-pyrrolo[3,4-c]pyrrole CCR5 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080103125-A1 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103125-A1 | Heterocylic antiviral compounds | CCR5, ACKR3, CXCR3 | ALDH1A1 1201/4885CCR8 21/4885ABL1 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.